Drug Trial Radar · NCT06225596
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
375
Planned (sponsor's estimate)
Start
Jan 24, 2024
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- BicycleTx LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, multicenter, randomized, open-label study. The main objective of the study is to measure the clinical activity and safety of zelenectide pevedotin formally BT8009, in combination with pembrolizumab versus chemotherapy, and as monotherapy in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection for zelenectide pevedotin and is comprised of 2 cohorts. Cohort 1 will include participants who have not received any prior systemic therapy for locally advanced or metastatic UC and are eligible to receive platinum-based chemotherapy, whereas Cohort 2 will include participants who have received ≥ 1 prior systemic therapy for locally advanced or metastatic UC.
Conditions
- Metastatic Urothelial Cancer
Interventions
Zelenectide pevedotinDrug
Participants will receive zelenectide pevedotin on Days 1, 8, and 15 of every 21-day cycle.
Zelenectide pevedotinDrug
Participants will receive zelenectide pevedotin on Days 1 and 8 of every 21-day cycle.
PembrolizumabDrug
Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the zelenectide pevedotin infusion.
Gemcitabine + cisplatin Or carboplatinDrug
Participants will receive Gemcitabine on Days 1 and 8 of every 21-day cycle plus cisplatin Or carboplatin on Day 1 of every 21-day cycle.
AvelumabDrug
After 4-6 cycles of Gemcitabine + Cisplatin or Carboplatin participants will receive maintenance Avelumab, if clinically indicated, on Days 1 and 15 each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1(RECIST v1.1) by blinded central independent review (BICR) of optimal dose zelenectide pevedotin with pembrolizumab versus chemotherapyTime frame: Up to approximately 4 years
- Cohort 2: PFS per RECIST v1.1 assessed by BICR of zelenectide pevedotin monotherapy in each treatment regimenTime frame: Up to approximately 4 years
- Cohort 2: Objective response rate (ORR) per RECIST v1.1 assessed by BICR of zelenectide pevedotin monotherapy in each treatment regimenTime frame: Up to approximately 4 years
Locations
102 sites in 21 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Center
Denver, Colorado
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida
Mount Sinai Medical Center of Florida, Inc.
Miami Beach, Florida
Moffitt
Tampa, Florida
University of Kansas Cancer Center
Westwood, Kansas
UofL Health Brown Cancer Center
Louisville, Kentucky
Nebraska Cancer Specialists
Omaha, Nebraska
Montefiore Medical Center
The Bronx, New York
Medical University of South Carolina (MUSC) - Hollings Cancer Center
Charleston, South Carolina
Carolina Urologic Research Center
Myrtle Beach, South Carolina
SCRI Oncology Partners
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Centro de Diagnostico Urologico S.R.L.
Buenos Aires, Argentina
Hospital Britanico de Buenos Aires
Buenos Aires, Argentina
Hospital Sirio Libanes de Buenos Aires
Buenos Aires, Argentina
Instituto Alexander Fleming
Buenos Aires, Argentina
Fundacion Medica Rio Negro y Neuquen
Cipolletti, Argentina
Centro Medico Privado (CEMAIC)
Córdoba, Argentina
Fundación CORI para la investigación y Prevención del Cancer
La Rioja, Argentina
Centro De Investigacion Pergamino S.A.
Pergamino, Argentina
Instituto de Oncologia de Rosario
Santa Fe, Argentina
Clinica Viedma S.A.
Viedma, Argentina
Cancer Research SA
Adelaide, Australia
Mater Misericordiae Ltd, South Brisbane
Brisbane, Australia
Townsville Hospital and Health Service
Douglas, Australia
Barwon Health
Geelong, Australia
Calvary Mater Newcastle
Hunter, Australia
Sir Charles Gairdner Hospital
Nedlands, Australia
Blacktown Hospital
New South Wales, Australia
Icon Cancer Centre
South Brisbane, Australia
Gold Coast University Hospital
Southport, Australia
General Hospital Maria Middelares
Ghent, Belgium
University Hospital Gent
Ghent, Belgium
Fundacao PIO XII - Hospital de Amor
Barretos, Brazil
CEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina
Florianópolis, Brazil
Hospital Alemao Oswaldo Cruz
São Paulo, Brazil
McGill University Health Center
Québec, Canada
Princess Margaret Hospital
Toronto, Canada
Fundación Arturo López Pérez (FALP)
Santiago, Chile
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.